From Earlier: FDA Grants TearLab Osmolarity System CLIA Waiver Categorization
TearLab Corporation (Nasdaq: TEAR) announced today that it is in receipt of a communication from the U.S. Food and Drug Administration indicating that, based on a supervisory review of the Company's appeal, the Agency has granted its petition for a waiver under CLlA for the TearLab Osmolarity System. Upon the Company's submission of labeling acceptable to the Agency, the CLIA waiver will be issued.
(c) 2013 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.